Saltar al contenido
Merck

A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2013-12-18)
Nahla E El-Ashmawy, Rania M Khalil
RESUMEN

L-carnitine is an antioxidant and is found to be a protective agent against many diseases including cancer. This review illustrates the possible role of L-carnitine as an add-on therapy to breast cancer patients maintained on tamoxifen. The objectives of carnitine treatment are diverse: improving tamoxifen-related side effects, offering better cancer prognosis by reducing the risk of developing cancer recurrence or metastasis, and modulating the growth factors which may be, in part, a prospective illustration to overcome tamoxifen resistance. So, it could be recommended to supplement L-carnitine to breast cancer patients starting tamoxifen treatment.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Tamoxifeno, ≥99%
Sigma-Aldrich
L-Carnitine inner salt, synthetic, ≥98%
Supelco
Tamoxifeno, analytical standard
Sigma-Aldrich
Tamoxifen citrate salt, ≥99%
USP
Levocarnitine, United States Pharmacopeia (USP) Reference Standard
Levocarnitine, European Pharmacopoeia (EP) Reference Standard
Tamoxifen citrate for performance test, European Pharmacopoeia (EP) Reference Standard
Tamoxifen citrate, European Pharmacopoeia (EP) Reference Standard